COVID-19 vaccination in the UK: Addressing vaccine hesitancy

Sonawane, Kalyani; Troisi, Catherine L; Deshmukh, Ashish A.

doi:10.1016/j.lanepe.2020.100016

Cited by 41 publications

(35 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to our study, some of the reasons assigned for the great mistrust/distrust of these COVID-19 vaccines information on social media include; too much different social media information on vaccine makers, too much exposure to different social media for COVID-19 news, too much social media information the risk perceptions and safety of the COVID-19 vaccines, too much Information on COVID-19, and too much information on Vaccine hesitancy. These findings are in line with previous studies conducted on vaccine hesitancy by Sonawane et al (2021), Ipsos (2020b), Su et al (2020). Also, our study releveled that the fake news on social media, on the reaction from people purported to have inoculated the COVID-19 vaccines have also greatly contributed to the high levels of mistrust for COVID-19 vaccines, therefore, reducing COVID-19 vaccines mistrust/distrust on social media must be a global priority.…”

Section: Discussionsupporting

confidence: 91%

Unmasking COVID-19 Vaccine “Infodemic” in the Social Media

Demuyakor

Nyatuame

Obiri

2021

ONLINE J. COMMUN. MEDIA TECHNOL

View full text Add to dashboard Cite

The activities of the anti-vaccine crusaders and conspiracy theorists on social media platforms have influenced billions of people across the globe on the safety of the COVID-19 vaccines currently been used for immunizations. The increased social media mis/disinformation on the efficacies and safety of these vaccines developed have raised a global concern among all stakeholders. This study adopted a convenience sampling through an online survey to collect data from N=1800 participants (students) from five (5) public universities in Accra the national capital of Ghana, which is also the epicenter of the COVID-19 pandemic to examine their perceptions on the overabundance COVID-19 pandemic information on social media and how these pieces information consumption impacts their trust/mistrust/distrust in the COVID-19 vaccines. The findings of our study indicate that there exist vital levels of COVID-19 vaccines "infodemic" on social media and these overabundances of COVID-19 vaccine information on social media has caused great levels of fear and panic among the students and the public. We also found that, the high exposure to COVID-19 vaccine information on social media are associated with negative perceptions and higher levels of mistrust/distrust among the population. This study recommends that stakeholders such as WHO, policymakers, and accredited health institutions must embark on public health communication campaigns to educate the public on the credible sources of COVID-19 pandemic information on social media.

show abstract

Section: Discussionsupporting

confidence: 91%

Unmasking COVID-19 Vaccine “Infodemic” in the Social Media

Demuyakor

Nyatuame

Obiri

2021

ONLINE J. COMMUN. MEDIA TECHNOL

View full text Add to dashboard Cite

show abstract

“…Online surveys were carried out in UK to find out the attitude of general population towards a potential vaccine and more than one third of participating adults showed their mistrust in a potential vaccine 46 . Similar findings were obtained from a study conducted in France 47 .…”

Section: Resultssupporting

confidence: 64%

Decreasing transmission and initiation of countrywide vaccination: Key challenges for future management of COVID‐19 pandemic in Bangladesh

Molla

Disha

Yeasmin

et al. 2021

Health Planning & Management

View full text Add to dashboard Cite

With a fragile healthcare system, Bangladesh, much like other countries in South East Asia, struggled during the early days of COVID‐19 pandemic. In following months several encouraging initiatives were undertaken including nationwide lockdown, maintaining social distancing and setting up COVID‐19 dedicated laboratories and hospitals. Despite fear of an escalation in COVID‐19 transmission during the winter months like their European counterparts, fortunately infection rates subsided and Bangladesh came out largely unharmed. But the next phase of COVID‐19 pandemic management that includes viral transmission suppression and conduction of nationwide immunization program require several urgent steps from government of Bangladesh (GoB) and relevant stakeholders. This qualitative research piece discussed about issues including an urgent need to enhance critical care facilities around the country, especially in peripheral districts; ramping up COVID‐19 testing at existing laboratories in view of diagnosing each case, and ensuring vaccines for the vulnerable populations in the country. Furthermore, the researchers shed light on other issues including a need to reinforce a struggling healthcare workforce, encouraging people to take vaccine, proper maintenance of social distancing regulations, routine epidemiological surveillance, management of environment and biomedical waste and undertaking a holistic approach to combat the pandemic and its environmental and financial consequences.

show abstract

“…29 They attest to the efficacy of free-of-charge vaccination programs in promoting immunization against the virus while highlighting the need to strengthen efforts to address vaccine hesitancy. 21,23 Importantly, our findings also show that the large majority of children and teenagers, and a large proportion of young and middle-aged adults, lack anti-SARS-CoV-2 antibodies, leaving behind a large reservoir in the population to sustain transmission in the critical months to come.…”

Section: Discussionmentioning

confidence: 52%

“…Indeed, several studies have found a clear pattern of socioeconomic disparities in vaccine hesitancy, whereby a lower proportion of socioeconomically disadvantaged individuals report intention or willingness to get vaccinated against SARS-CoV-2 than more socioeconomically privileged individuals. [21][22][23][24][25][26] Strengths of this study include the large sample that is representative of the general population, the measurement of antibodies against both the SARS-CoV-2 S and N proteins, and the robust novel modelling framework accounting for both immunoassays and vaccination status. Limitations include the fact that, as with most seroprevalence surveys, 27 the sample was generally more socioeconomically advantaged than the general population (Table S4), which may have led to overestimation of vaccinederived antibody seroprevalence-however, the proportion of vaccinated individuals in our sample was similar to that observed in the general population of Geneva (Table S5); the fact that we only included formal residents and that we only assessed education as a socioeconomic indicator, which may have precluded the identification of inequalities based on other indicators; and, finally, the fact that, since we did not perform neutralization assays, our estimates may not completely reflect SARS-CoV-2 protective immunity.…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland

Stringhini

Zaballa

Pullen

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Up-to-date seroprevalence estimates are critical to describe the SARS-CoV-2 immune landscape in the population and guide public health measures. We aimed to estimate the seroprevalence of anti-SARS-CoV-2 antibodies 15 months into the COVID-19 pandemic and six months into the vaccination campaign. Methods: We conducted a population-based cross-sectional serosurvey between June 1 and July 7, 2021, recruiting participants from age- and sex-stratified random samples of the general population. We tested participants for anti-SARS-CoV-2 antibodies targeting the spike (S) or nucleocapsid (N) proteins (Roche Elecsys immunoassays). We estimated the anti-SARS-CoV-2 antibodies seroprevalence following vaccination and/or infection (anti-S antibodies), or infection only (anti-N antibodies). Results: We included 3355 individuals, of which 1814 (54.1%) were women, 697 (20.8%) were aged <18 years and 449 (13.4%) were aged ≥65 years, 2161 (64.4%) tested positive for anti-S antibodies, and 906 (27.0%) tested positive for anti-N antibodies. The total seroprevalence of anti-SARS-CoV-2 antibodies was 66.1% (95% credible interval, 64.1-68.0). Considering the presence of anti-N antibodies, we estimated that 29.9% (28.0-31.9) of the population developed antibodies after infection; the rest having developed antibodies only via vaccination. Seroprevalence estimates were similar across sexes, but differed markedly across age groups, being lowest among children aged 0-5 years (20.8% [15.5-26.7]) and highest among older adults aged ≥75 years (93.1% [89.6-96.0]). Seroprevalence of antibodies developed via infection and/or vaccination was higher among participants with a higher educational level. Conclusions: Most adults have developed anti-SARS-CoV-2 antibodies, while most teenagers and children remain vulnerable to infection. As the SARS-CoV-2 Delta variant spreads and vaccination rates stagnate, efforts are needed to address vaccine hesitancy, particularly among younger individuals and socioeconomically disadvantaged groups, and to minimize spread among children.

show abstract

COVID-19 vaccination in the UK: Addressing vaccine hesitancy

Cited by 41 publications

References 5 publications

Unmasking COVID-19 Vaccine “Infodemic” in the Social Media

Unmasking COVID-19 Vaccine “Infodemic” in the Social Media

Decreasing transmission and initiation of countrywide vaccination: Key challenges for future management of COVID‐19 pandemic in Bangladesh

Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland

Contact Info

Product

Resources

About